The objective of the current study is initially to use our cohort of 429 conservatively managed prostate cancer cases to assess the potential clinical significance of ETV1 gene alterations and in parallel to assess the relative frequency of each of the known ETV1 fusion partners. The gene discussed is ETV1; the disease is prostate cancer.